Diet Drug Report for June 2006 -- News About Diet Drugs
Pfizer Licenses Promising Diet Drug in Early Trials From Bayer
Pfizer Inc. on June 14th expanded its efforts to become a major player in the development of prescription diet drugs, announcing it is licensing from Bayer Pharmaceuticals Corporation exclusive worldwide rights to Bayer's DGAT-1 inhibitors, an innovative class of compounds that modify lipid metabolism.
The lead compound in the class, BAY 74-4113, which is currently in Phase I trials, is a potential treatment for obesity, type 2 diabetes and other related disorders.
"We are excited about the potential of the DGAT-1 inhibitors in the areas of obesity and type 2 diabetes which complement Pfizer's ongoing metabolic disease research programs," said Martin Mackay, senior vice president, Worldwide Research & Technology for Pfizer.
Pfizer already has a cannabinoid CB1 receptor antagonist, CP-945598, which has shown promise as a treatment for obesity that has made it through Phase I trials. French pharmaceutical company Sanofi-Aventis is hoping to receive European approval for its CB1 receptor antagonist, Acomplia (rimonabant), in less than a month.
Under the terms of the agreement, Bayer will receive an upfront fee, milestone payments and royalties on sales of any drug that is successfully brought to market.
The agreement is subject to U.S. antitrust approval and the two companies said they expect it to close in the second half of 2006.
We subscribe to the HONcode principles of the HON Foundation.
This is an independent news site reporting on prescription and over-the-counter diet drugs and on the more than 200 additional diet drugs currently in various stages of development. . Nothing on this site is intended to infringe on any trademarks. Nothing on this site is intended as medical advice. The information provided is for informational purposes only. Always consult a doctor or medical professional with questions regarding a medical condition.
Copyright 2004-2006 Medical Week News, Inc. All Rights Reserved